Report by : Gan Yung Chyan
/ KUCINTA SETIA
An international team that consists of researchers affiliated with the University of Washington and Institut Pasteur published a report in the British academic journal Nature on 18 May 2020, announcing they have isolated antibodies from patients with severe acute respiratory syndrome (SARS) who have recovered. It can effectively inhibit SARS-CoV-2 (covi, in short) in the laboratory, which may help to develop drugs or vaccines against covi.
The researchers mentioned that they isolated several antibodies from a patient who was infected with SARS-CoV in 2003 but then recovered. Previously, these antibodies have been found to inhibit SARS-related coronavirus from humans and animals.
After the outbreak of the covid epidemic, they found that an antibody coded S309 showed a strong inhibitory ability against SARS-CoV-2 in the experiment. If S309 is used in combination with another relatively weak antibody, it can further enhance the neutralization effect of covi, and at the same time reduce the probability of resistance mutations.
The researchers said that because the S309 antibody can cover a wide range of coronaviruses, even if covi continues to evolve, it is not easy to develop resistance to this antibody.
However, this study is only a preliminary exploration of the potential effects of related antibodies on the new coronavirus, and no clinical trials have been carried out. The researchers said that they are advancing the research and development of related drugs and are expected to carry out clinical trials in the near future.
Ref :
Dora Pinto et al., Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature,
https://www.nature.com/articles/s41586-020-2349-y
/ KUCINTA SETIA
An international team that consists of researchers affiliated with the University of Washington and Institut Pasteur published a report in the British academic journal Nature on 18 May 2020, announcing they have isolated antibodies from patients with severe acute respiratory syndrome (SARS) who have recovered. It can effectively inhibit SARS-CoV-2 (covi, in short) in the laboratory, which may help to develop drugs or vaccines against covi.
The researchers mentioned that they isolated several antibodies from a patient who was infected with SARS-CoV in 2003 but then recovered. Previously, these antibodies have been found to inhibit SARS-related coronavirus from humans and animals.
After the outbreak of the covid epidemic, they found that an antibody coded S309 showed a strong inhibitory ability against SARS-CoV-2 in the experiment. If S309 is used in combination with another relatively weak antibody, it can further enhance the neutralization effect of covi, and at the same time reduce the probability of resistance mutations.
The researchers said that because the S309 antibody can cover a wide range of coronaviruses, even if covi continues to evolve, it is not easy to develop resistance to this antibody.
However, this study is only a preliminary exploration of the potential effects of related antibodies on the new coronavirus, and no clinical trials have been carried out. The researchers said that they are advancing the research and development of related drugs and are expected to carry out clinical trials in the near future.
Ref :
Dora Pinto et al., Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature,
https://www.nature.com/articles/s41586-020-2349-y
No comments:
Post a Comment